Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach

World Journal of Gastroenterology

Volumn 15, Issue 7, 2009, Pages 853-859

  Iijima, Katsunori ^a   Abe, Yasuhiko ^a   Kikuchi, Ryosuke ^a   Koike, Tomoyuki ^a   Ohara, Shuichi ^a   Sipponen, Pentti ^b   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JORVI HOSPITAL   (Finland)

Author keywords

Gastric atrophy; Helicobacter pylori; Serum gastrin 17; Serum pepsinogen

Indexed keywords

BIOLOGICAL MARKER; GASTRIN 17; PEPSINOGEN I; PEPSINOGEN II; GASTRIN; PEPSINOGEN;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH CANCER; STOMACH MUCOSA; BIOPSY; BLOOD; ENZYMOLOGY; GASTRITIS; JAPAN; MICROBIOLOGY; MIDDLE AGED; OUTPATIENT; PATHOLOGY; PHYSIOLOGY; PREVALENCE; REFERENCE VALUE; RISK FACTOR; STOMACH; STOMACH TUMOR;

ADULT; AGED; BIOPSY; DIAGNOSIS, DIFFERENTIAL; GASTRINS; GASTRITIS; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MIDDLE AGED; OUTPATIENTS; PEPSINOGEN A; PEPSINOGEN C; PEPTIC ULCER; PREVALENCE; REFERENCE VALUES; RISK FACTORS; STOMACH; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 65649150312     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.853     Document Type: Article

References (40)

1. IARC monographs on the evaluation of carcinogenic risks to humans. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon: International Agency for Research on Cancer, 1994; 61: 218-220
2. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996; 31: 546-550
3. Maaroos HI, Vorobjova T, Sipponen P, Tammur R, Uibo R, Wadstrom T, Keevallik R, Villako K. An 18-year follow-up study of chronic gastritis and Helicobacter pylori association of CagA positivity with development of atrophy and activity of gastritis. Scand J Gastroenterol 1999; 34: 864-869
4. Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985; 35: 173-177
5. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789
6. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, Tannenbaum S, Collazos T, Ruiz B. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50: 4737-4740
7. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M, Prijon T. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57: 324-329
8. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, Shimizu Y, Takeshita T, Mohara O, Ichinose M. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109: 138-143
9. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194
10. Sipponen P, Seppala K, Aarynen M, Helske T, Kettunen P. Chronic gastritis and gastroduodenal ulcer: a case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis. Gut 1989; 30: 922-929
11. Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 2007; 42: 2-10
12. Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16: 1449-1456
13. Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Megraud F, Xiao SD, Sugano K, Nyren O. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005; 100: 2100-2115
14. Borody TJ, Andrews P, Jankiewicz E, Ferch N, Carroll M. Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. Am J Gastroenterol 1993; 88: 1266-1268
15. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
16. Karnes WE Jr, Samloff IM, Siurala M, Kekki M, Sipponen P, Kim SW, Walsh JH. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991; 101: 167-174
17. Varis K, Kekki M, Harkonen M, Sipponen P, Samloff IM. Serum pepsinogen I and serum gastrin in the screening of atrophic pangastritis with high risk of gastric cancer. Scand J Gastroenterol Suppl 1991; 186: 117-123
18. Knight T, Wyatt J, Wilson A, Greaves S, Newell D, Hengels K, Corlett M, Webb P, Forman D, Elder J. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. Br J Cancer 1996; 73: 819-824
19. Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer 2003; 88: 1239-1247
20. Aromaa A, Kosunen TU, Knekt P, Maatela J, Teppo L, Heinonen OP, Harkonen M, Hakama MK. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol 1996; 144: 142-149
21. Borch K, Axelsson CK, Halgreen H, Damkjaer Nielsen MD, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand J Gastroenterol 1989; 24: 870-876
22. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003; 98: 735-739
23. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44: 693-697
24. Kiyohira K, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K. Serum pepsinogen concentration as a marker of Helicobacter pyloriinfection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol 2003; 38: 332-338
25. Shiotani A, Iishi H, Uedo N, Kumamoto M, Nakae Y, Ishiguro S, Tatsuta M, Graham DY. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 2005; 115: 463-469
26. Urita Y, Hike K, Torii N, Kikuchi Y, Kanda E, Sasajima M, Miki K. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci 2004; 49: 795-801
27. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764-768
28. Sipponen P, Ranta P, Helske T, Kaariainen I, Maki T, Linnala A, Suovaniemi O, Alanko A, Harkonen M. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 2002; 37: 785-791
29. Vaananen H, Vauhkonen M, Helske T, Kaariainen I, Rasmussen M, Tunturi-Hihnala H, Koskenpato J, Sotka M, Turunen M, Sandstrom R, Ristikankare M, Jussila A, Sipponen P. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885-891
30. Pasechnikov VD, Chukov SZ, Kotelevets SM, Mostovov AN, Mernova VP, Polyakova MB. Possibility of noninvasive diagnosis of gastric mucosal precancerous changes. World J Gastroenterol 2004; 10: 3146-3150
31. Sipponen P, Valle J, Varis K, Kekki M, Ihamaki T, Siurala M. Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects. Scand J Gastroenterol 1990; 25: 513-519
32. Kuipers EJ, Pals G, Pena AS, van Uffelen CW, Kok A, Westerveld BD, Meuwissen SG. Helicobacter pylori, pepsinogens and gastrin: relationship with age and development of atrophic gastritis. Eur J Gastroenterol Hepatol 1996; 8: 153-156
33. Farinati F, Di Mario F, Plebani M, Cielo R, Fanton MC, Valiante F, Masiero M, De Boni M, Della Libera G, Burlina A. Pepsinogen A/pepsinogen C or pepsinogen A multiplied by gastrin in the diagnosis of gastric cancer? Ital J Gastroenterol 1991; 23: 194-196
34. Sipponen P, Vauhkonen M, Helske T, Kaariainen I, Harkonen M. Low circulating levels of gastrin-17 in patients with Barrett's esophagus. World J Gastroenterol 2005; 11: 5988-5992
35. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9: 245-253
36. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. Jpn J Cancer Res 1995; 86: 1210-1215
37. Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, Doi Y, Shikata K, Yonemoto K, Shirota T, Matsumoto T, Iida M. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006; 163: 629-637
38. Plummer M, Buiatti E, Lopez G, Peraza S, Vivas J, Oliver W, Munoz N. Histological diagnosis of precancerous lesions of the stomach: a reliability study. Int J Epidemiol 1997; 26: 716-720
39. Rugge M, Correa P, Dixon MF, Fiocca R, Hattori T, Lechago J, Leandro G, Price AB, Sipponen P, Solcia E, Watanabe H, Genta RM. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002; 16: 1249-1259
40. van Grieken NC, Weiss MM, Meijer GA, Bloemena E, Lindeman J, Offerhaus GJ, Meuwissen SG, Baak JP, Kuipers EJ. Rapid quantitative assessment of gastric corpus atrophy in tissue sections. J Clin Pathol 2001; 54: 63-69